- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03482960
Comparison of 129Xe MRI With 19F MRI in CF Lung Disease
January 21, 2021 updated by: University of North Carolina, Chapel Hill
This study is designed to compare the capabilities of two novel imaging techniques: polarized perfluorinated gas mixed with oxygen, and hyperpolarized xenon mixed with N2 to detect changes in lung ventilation using MRI.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The goal of this study is to compare the capabilities of two novel imaging techniques: conventional 'thermally' polarized perfluorinated gases (perfluoropropane, or PFP) mixed with oxygen, and hyperpolarized xenon (129Xe) mixed with N2 to detect changes in lung ventilation using magnetic resonance imaging (MRI).
Although considerable work has been done internationally with hyperpolarized xenon MRI, the low availability and high cost of this technique is limiting.
Perfluorinated gas MRI is an alternative that may in fact be a suitable, simpler alternative.
PFP is commercially availability in large quantities, which allows multiple breath studies and thus provides the ability to analyze gas wash-in and wash-out kinetics.
These endpoints may improve the investigators ability to detect ventilation abnormalities beyond the traditional "ventilation defect percentage" parameter obtained with 129Xe MRI.
The commercial availability of PFP and lack of need for onsite hyperpolarization may also facilitate the transfer of this technology to other centers for the conduct of multicenter studies.
The investigators hypothesize that 19F MRI will not be inferior to hyperpolarized xenon MRI in detection of ventilation defect percentages (VDP).
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- The University of North Carolina at Chapel Hill
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Subjects with CF must meet all of the following inclusion criteria to be eligible for enrollment:
- Subjects must be at least 18 years of age;
- Non-smokers (<10 pack year history and no active smoking in the past year);
- Diagnosis of cystic fibrosis as via standard sweat chloride/phenotypic features/genotyping
- Stable lung disease as evidenced by no change in respiratory medications or change in forced expiratory volume in 1 second (FEV1) of >15% from baseline over the preceding 4 weeks prior to enrollment
- Baseline FEV1 >70% of predicted.
- No use of supplemental oxygen
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial
- Subjects must be willing and able to comply with scheduled visits and other trial procedures.
Subjects without CF must meet all of the following inclusion criteria to be eligible for enrollment:
- Subjects must be at least 18 years of age;
- Non-smokers (<10 pack year history and no active smoking in the past year);
- Baseline FEV1 >70% of predicted.
- No use of supplemental oxygen or clinically significant lung disease
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial
- Subjects must be willing and able to comply with scheduled visits and other trial procedures.
Exclusion Criteria:
- Active or past smokers with less than 1 years since quitting or >10 pack-year smoking history
- Co-existent asthma (as evidenced by either clinical diagnosis, chronic oral steroid use, or marked broncho-reactivity on pulmonary function testing)
Unable to undergo a 3.0-Tesla MRI exam of the lungs and chest because of contraindications including
- Occupation (past or present) of machinist, welder, grinder;
- Injury to the eye involving a metallic object
- Injury to the body by a metallic object (bullet, BB, shrapnel)
- Presence of a cardiac pacemaker or defibrillator
- Presence of aneurysm clips
- Presence of carotid artery vascular clamp
- Presence of neurostimulator
- Presence of insulin or infusion pump
- Presence of implanted drug infusion device that is not known to be MRI compatible (i.e., was placed outside of UNCH or is older than 10 years)
- Bone growth or fusion simulator
- Presence of cochlear, otologic or ear implant
- Any type of prosthesis (eye, penile, etc.)
- Artificial limb or joint
- Non-removable electrodes (on body, head or brain)
- Intravascular stents, filters or coils
- Shunt (spinal or intraventricular)
- Swan-ganz catheter
- Any implant held in place by a magnet
- Transdermal delivery system (e.g. Nitro)
- Intrauterine Device (IUD) or diaphragm
- Tattooed makeup (eyeliner, lips, etc.) or tattoos covering >25% of body surface area
- Body piercings (MUST BE REMOVED BEFORE MRI)
- Any metal fragments
- Internal pacing wires
- Metal or wire mesh implants
- Hearing aid (REMOVE BEFORE MRI)
- Dentures (REMOVE BEFORE MRI)
- Claustrophobia
- Unable to tolerate inhalation of gas mixture
- Any changes in medications that may affect CF lung disease in the past 14 days, including any experimental therapies
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
- Pregnancy; women of childbearing potential must have a confirmed negative urine pregnancy test on the day of the MRI scan, prior to the MRI scan.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 129Xe MRI
Participants will self-administer hyperpolarized xenon gas via inhalation prior to the investigators acquiring MRI images.
MRI imaging will be taken during approximately 15-second breath-holds.
After the MRI is complete, participant performs spirometry maneuvers in a room outside the magnet.
Once a minimum of 15 minutes has elapsed since leaving the MRI scanner, the participant will return to the MRI scanner, where the second phase of the study will occur.
PFP gas will be administered using a full-face mask during the MRI.
Images are acquired during 12-second breath-hold after every 3rd breath.
|
Hyperpolarized Xenon gas
Other Names:
Other Names:
|
Experimental: 19F MRI with PFP
PFP gas will be administered using a full-face mask during the MRI.
Images are acquired during 12-second breath-hold after every 3rd breath.
After the MRI is complete, participant performs spirometry maneuvers in a room outside the magnet.
Once a minimum of 15 minutes has elapsed since leaving the MRI scanner, the participant returns to the MRI scanner, where he/she will self-administer hyperpolarized xenon gas prior to acquiring MRI images.
MRI imaging will be taken during approximately 15-second breath-holds.
|
Hyperpolarized Xenon gas
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Volume of unventilated lung area after a single 129Xe inhalation and after each inhalation cycle with PFP
Time Frame: 1 hour
|
Primary comparison will be the VDP with Xenon (single breath) and after first PFP inhalation cycle (3 breaths of PFP)
|
1 hour
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Signal-to-noise (SNR) of each modality
Time Frame: 20 minutes
|
Assessment of the quality of signal achieved with each modality
|
20 minutes
|
Rate constant describing wash-in and wash-out of PFP
Time Frame: 15 minutes
|
change in ventilated areas of the lung over time when administered PFP
|
15 minutes
|
Correlation between VDP identified by each modality and spirometry and Lung Clearance Index (LCI)
Time Frame: 2 hours
|
Comparison of VDP to two standard metrics of lung function, spirometry and LCI
|
2 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Jennifer Goralski, MD, University of North Carolina, Chapel Hill
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 29, 2018
Primary Completion (Actual)
April 9, 2019
Study Completion (Actual)
April 10, 2019
Study Registration Dates
First Submitted
March 23, 2018
First Submitted That Met QC Criteria
March 23, 2018
First Posted (Actual)
March 29, 2018
Study Record Updates
Last Update Posted (Actual)
January 25, 2021
Last Update Submitted That Met QC Criteria
January 21, 2021
Last Verified
September 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-2569
- XePFP2017 (Other Identifier: University of North Carolina at Chapel Hill)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
Clinical Trials on Hyperpolarized Xenon gas
-
The Hospital for Sick ChildrenRecruitingHealthy VolunteersCanada
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences InstituteRecruiting
-
The Hospital for Sick ChildrenUniversity Health Network, TorontoRecruiting
-
Children's Hospital Medical Center, CincinnatiNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Bastiaan DriehuysNational Heart, Lung, and Blood Institute (NHLBI)CompletedRadiation InjuryUnited States
-
Bastiaan DriehuysNational Heart, Lung, and Blood Institute (NHLBI); University of Wisconsin,...CompletedIdiopathic Pulmonary FibrosisUnited States
-
The Hospital for Sick ChildrenWestern UniversityTerminatedLung Structure-Function In SurVivors of Mild and SEvere COVID-19 Infection: 129Xe MRI (LivCovidFree)COVID-19 Respiratory InfectionCanada
-
Duke UniversityBoehringer IngelheimRecruitingIdiopathic Pulmonary Fibrosis | Progressive Pulmonary FibrosisUnited States
-
Oxford University Hospitals NHS TrustNational Institute for Health Research, United KingdomCompleted
-
Duke UniversityActive, not recruiting